The aim of this exploratory study is to investigate whether the CSF/plasma albumin quotient (Q-Alb) and CSF platelet-derived growth factor-β (PDGFR-β) can be used as biomarkers for BBB/BCB integrity in HD and if there is an association between Q-Alb and the prevalence of intrathecal Th17.1 cells in HDGECs. This evidence concerns the gene ALB and Huntington disease.